tiprankstipranks
Trending News
More News >
OptimizeRx Corporation (OPRX)
NASDAQ:OPRX
US Market
Advertisement

OptimizeRx (OPRX) Earnings Dates, Call Summary & Reports

Compare
551 Followers

Earnings Data

Report Date
Feb 19, 2026
TBA (Confirmed)
Period Ending
2025 (Q4)
Consensus EPS Forecast
0.25
Last Year’s EPS
0.3
Same Quarter Last Year
Based on 6 Analysts Ratings

Earnings Call Summary

Q3 2025
Earnings Call Date:Nov 06, 2025|
% Change Since:
|
Earnings Call Sentiment|Positive
The earnings call reflected strong financial performance in Q3 with significant revenue and EBITDA growth, increased guidance for the current and following fiscal year, and strategic debt reduction. Despite these achievements, expectations for Q4 are conservative, and operating expenses have increased due to higher variable compensation. Overall, the sentiment is positive, with a focus on continued growth and operational excellence.
Company Guidance
During OptimizeRx's third-quarter fiscal year 2025 earnings call, the company reported a 22% year-over-year increase in Q3 revenues, reaching $26.1 million, and a significant improvement in adjusted EBITDA, which rose to $5.1 million, an increase of over $2 million from the previous year. The company announced upward revisions to its full-year guidance, now expecting 2025 revenues between $105 million and $109 million and adjusted EBITDA between $16 million and $19 million. Additionally, OptimizeRx introduced initial guidance for fiscal year 2026, projecting revenues between $118 million and $124 million, with adjusted EBITDA anticipated to be between $19 million and $22 million. The company highlighted a successful focus on operational excellence, evidenced by strong contracted revenue growth and improvements in average revenue per customer, with the top 5 customers generating over $11 million each. OptimizeRx also emphasized its strategic efforts in enhancing gross margins, primarily driven by favorable product mix and economies of scale, and announced plans to continue accelerating debt repayment, reducing its term loan principal by an additional $2 million beyond the scheduled payments.
Strong Third Quarter Performance
Q3 revenues increased 22% year-over-year to $26.1 million, with adjusted EBITDA at $5.1 million, an improvement of over $2 million from the same period last year.
Increased Guidance for 2025 and 2026
Guidance updated to $105 million - $109 million in revenue for 2025, with adjusted EBITDA between $16 million and $19 million. Initial guidance for 2026 projects revenue of $118 million to $124 million and adjusted EBITDA of $19 million to $22 million.
Operational Excellence and Debt Reduction
Paid down an additional $2 million on the term loan principal, with a total principal paydown for the year at $7.5 million. The company intends to continue debt reduction at an accelerated rate.
Gross Margin Expansion
Gross margin increased from 63.1% in Q3 2024 to 67.2% in Q3 2025, driven by favorable product mix and economies of scale.
Positive RFP Trends
Favorable RFP trends for 2026 with increased interest in both HCP and DTC channels, suggesting continued growth potential.

OptimizeRx (OPRX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

OPRX Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Feb 19, 2026
2025 (Q4)
0.25 / -
0.3
Nov 06, 2025
2025 (Q3)
0.04 / 0.20
0.1266.67% (+0.08)
Aug 07, 2025
2025 (Q2)
0.02 / 0.24
0.021100.00% (+0.22)
May 12, 2025
2025 (Q1)
-0.12 / 0.08
-0.11172.73% (+0.19)
Mar 12, 2025
2024 (Q4)
0.27 / 0.30
0.2615.38% (+0.04)
Nov 13, 2024
2024 (Q3)
0.06 / 0.12
0.0933.33% (+0.03)
Aug 08, 2024
2024 (Q2)
-0.06 / 0.02
-0.01300.00% (+0.03)
May 14, 2024
2024 (Q1)
- / -
-0.09
Apr 16, 2024
2023 (Q4)
-0.13 / -0.11
-0.09-22.22% (-0.02)
Nov 06, 2023
2023 (Q3)
0.03 / 0.09
0.0728.57% (+0.02)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

OPRX Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Nov 06, 2025
$18.94$15.65-17.37%
Aug 07, 2025
$12.84$17.30+34.74%
May 12, 2025
$9.20$11.01+19.67%
Mar 12, 2025
$4.14$6.28+51.69%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does OptimizeRx Corporation (OPRX) report earnings?
OptimizeRx Corporation (OPRX) is schdueled to report earning on Feb 19, 2026, TBA (Confirmed).
    What is OptimizeRx Corporation (OPRX) earnings time?
    OptimizeRx Corporation (OPRX) earnings time is at Feb 19, 2026, TBA (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is OPRX EPS forecast?
          OPRX EPS forecast for the fiscal quarter 2025 (Q4) is 0.25.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis